
About Meiogenix
Meiogenix is a Healthcare company based in Paris (France) founded in 2010. Novel breeding technologies for crop plants are developed. It operates in the Healthcare and Agriculture sectors. Meiogenix has raised $13 million across 3 funding rounds from investors including ARE, Bpifrance and Kurma Partners. Its chief executive, as recorded, is Luc Mathis. Meiogenix offers products and services including Chromosome Editing. Its focus areas include Life Sciences, Genomics, Applied Genomics and Agrigenomics. Its legal entity is Meiogenix Inc.
Company details
Meiogenix was founded in 2010 and is based in Paris, France. Operations focus on the agricultural biotechnology sector, where novel breeding technologies for crop plants are developed. A fusion protein platform is utilized to enhance recombination rates in cold regions. Solutions aimed at improving crop resilience, quality, and yield are pursued through these technologies.
- Headquarters Paris, France
- SectorsHealthcareAgriculture
- Emailβ’β’β’β’β’β’β’β’
- Website meiogenix.com
- Social LinkedIn
- Legal Name Meiogenix Inc.
- Total Equity Funding$13M (USD)
in 3 rounds
- Latest Funding Round$13M (USD), Series A
Dec 2021
- InvestorsARE
& 5 more
Products & Services of Meiogenix
Meiogenix offers a comprehensive portfolio of products and services, including Chromosome Editing.
Edits crop chromosomes to unlock genetic diversity for addressing farming challenges.
Funding Insights of Meiogenix
Meiogenix has successfully raised a total of $13M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $13 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13M
- Total Rounds 3
- Last Round Series A β $13M
- Investors Count 6
All 3 funding rounds of Meiogenix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $13M | Series A | β | Sofinnova Partners | |
| Apr 2016 | $1.6M | Grant | β | β | β |
| Nov 2010 | Series A | β | β |
6 investors in total: 6 institutional.
Investors in Meiogenix
Meiogenix has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Bpifrance and Kurma Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Early-stage VC firm focused on life science startups | genoavc.com | San Francisco, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States |
Investor details for Meiogenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Meiogenix
10 people are tracked at Meiogenix (3 in leadership, 6 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Luc Mathis | CEO | Leadership |
Gaganpreet Sidhu | Chief Technology Officer | Leadership |
Virginie Alexanian | CFO | Leadership |
Benoit Barteau | Director | Board & advisors |
Johan Cardoen | Chairman | Board & advisors |
Wojtek P. Pawlowski | Scientific Advisor | Board & advisors |
Michael Krel | Director | Board & advisors |
Jenny Rooke | Director | Board & advisors |
Neal Gutterson | Director | Board & advisors |
Alain Nicolas | CSO | Team |
Complete people profiles for Meiogenix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Meiogenix
3 dated milestones of Meiogenix across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Meiogenix is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $13.0M.
Web traffic of Meiogenix
The website of Meiogenix (meiogenix.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 46.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Meiogenix
Complete news archive for Meiogenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Meiogenix
Meiogenix was founded in 2010.
Meiogenix is headquartered in Paris, France.
Luc Mathis is the CEO of Meiogenix, as recorded in our data.
Meiogenix is a funded company, having raised a total of $13M across 3 funding rounds to date.
Meiogenix was founded in 2010 and is based in Paris, France. Operations focus on the agricultural biotechnology sector, where novel breeding technologies for crop plants are developed. A fusion protein platform is utilized to enhance recombination rates in cold regions. Solutions aimed at improving crop resilience, quality, and yield are pursued through these technologies.
Meiogenix offers Chromosome Editing.
Meiogenix has 6 investors. Key investors include ARE, Bpifrance, Kurma Partners, Sofinnova Partners, and Genoa Ventures.
Meiogenix operates through Meiogenix Inc..
